CNBC
09 Jul 2026, 07:34 UTC · 2h ago
AstraZeneca stock dives 9% after heart drug trial misses target
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
09 Jul 2026, 07:34 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AstraZeneca's late-stage clinical trial for the heart disease medicine Wainua failed to meet its primary goal of reducing deaths and recurrent heart-related emergencies. — Failure of a late-stage trial for a life-threatening condition leads to immediate loss of potential revenue and investor confidence in the pipeline.
-0.80AstraZeneca shares fell nearly 9% in London, marking the stock's worst day since March 2020. — The significant price drop reflects a sharp correction in market valuation based on the clinical failure.
-0.50A Jefferies analyst stated that the trial failure does not jeopardize AstraZeneca's $80 billion sales target for 2030. — This provides a floor for the stock by suggesting the company's long-term financial goals remain intact despite this specific setback.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares fell nearly 9% following the failure of a late-stage clinical trial for the heart disease medicine Wainua.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
